Academic History
Rami Komrokji, MD, is a board-certified hematologist and currently serves as Vice Chair of the Malignant Hematology Department and Senior Member of the Malignant Hematology and Experimental Therapeutics Program at Moffitt Cancer Center, Tampa, FL. He also holds a joint academic appointment as Professor of Medicine and Oncologic Sciences at the University of South Florida College of Medicine, Tampa, FL.
Dr Komrokji received his medical degree from the Jordan University School of Medicine, Amman, Jordan. He completed his internship and residency in internal medicine at Case Western Reserve University, Cleveland, OH, followed by a fellowship in Hematology, Oncology and Hematopoietic Stem Cell Transplantation at Strong Memorial Hospital, University of Rochester, Rochester, NY. He has held numerous leadership and advisory roles, including serving on the MDS Panel for the National Comprehensive Cancer Network (NCCN), the steering committee for the NHLBI MDS Natural History Study, and the Medical Board of Directors for the Aplastic Anemia and MDS Foundation. He has also served on the editorial board of the Journal of Clinical Oncology and is a frequent peer reviewer for leading journals such as Blood, JCO, and Leukemia.
Speaking on treatments for myeloid malignancies
Dr Komrokji specializes in the management and clinical research of myeloid malignancies, with a particular focus on early-phase drug development for myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms (MPNs). He has led numerous clinical trials, several of which contributed directly to the FDA approval of novel therapies, including luspatercept for MDS and pacritinib for myelofibrosis. Dr Komrokji is widely recognized for his contributions to advancing treatment strategies and outcome research in hematologic cancers.
